Magnetic resonance imaging and spectroscopy in hypomyelinating leukodystrophy
Brain and Development · 2025
DOI: 10.1016/j.braindev.2025.104345 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Brain and Development, 2025. Verfasst von Jun-Ichi Takanashi. Beteiligte Einrichtung: Department of Pediatrics, Tokyo Women's Medical University Yachiyo Medical Center, 477-96 Owadashinden, Yachiyo-Shi, Chiba 276-8524, Japan. Electroni…. Hauptthemen laut MEDLINE: Magnetic Resonance Imaging, Hereditary Central Nervous System Demyelinating Diseases, Brain. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Government of Japan Ministry of Health Labour and Welfare, Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Recent advancements in molecular biology and radiology have led to the identification of several new leukodystrophies. A key diagnostic feature of leukodystrophies is the increased white matter signal intensity observed on T2-weighted magnetic resonance (MR) images. Leukodystrophies are typically classified into two main categories: hypomyelinating leukodystrophies (HLD) and other forms, including demyelinating leukodystrophies. HLD is characterized by a primary defect in myelin due to genetic variants that affect structural myelin proteins, oligodendrocyte transcription factors, RNA translation, and lysosomal proteins. Radiologically, HLD tends to show less pronounced white matter hyperintensity on T2-weighted images than demyelinating leukodystrophies. A definitive diagnosis can often be made by identifying abnormalities in regions beyond the white matter, such as the basal ganglia or cerebellum, or through the presence of characteristic clinical symptoms. N-acetylaspartate, a neuroaxonal marker observed on MR spectroscopy, is typically reduced in many neurological conditions, but N-acetylaspartate levels often remain normal in HLD, which is considered a distinctive feature of this disorder. This article provides an overview of the latest imaging findings and clinical features associated with HLD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Tokyo Women's Medical University Yachiyo Medical Center, 477-96 Owadashinden, Yachiyo-Shi, Chiba 276-8524, Japan. Electronic address: jtaka@twmu.ac.jp.
Förderung
- Government of Japan Ministry of Health Labour and Welfare
- Japan Society for the Promotion of Science
- Japan Agency for Medical Research and Development
Zitieren
APA
Takanashi, J. I. (2025). Magnetic resonance imaging and spectroscopy in hypomyelinating leukodystrophy. Brain and Development. https://doi.org/10.1016/j.braindev.2025.104345
Vancouver
Takanashi JI. Magnetic resonance imaging and spectroscopy in hypomyelinating leukodystrophy. Brain and Development. 2025. doi:10.1016/j.braindev.2025.104345
BibTeX
@article{Takanashi2025,
author = {Takanashi, Jun-Ichi},
title = {Magnetic resonance imaging and spectroscopy in hypomyelinating leukodystrophy},
journal = {Brain and Development},
year = {2025},
doi = {10.1016/j.braindev.2025.104345}
}
EUVIMED